10 consecutive upper circuits in this multibagger specialty chemicals & pharma stock; Earlier company incorporated a new subsidiary for business expansion!
The stock gave multibagger returns of 371.65 per cent from its 52-week low of Rs 58.20 per share.
Today, shares of Sudarshan Pharma Industries Ltd hit a 5 per cent upper circuit to an intraday high of Rs 274.50 per share from its previous closing of Rs 261.45 per share. The stock also made a new 52-week high of Rs 274.50 per share while its 52-week low is Rs 58.20 per share. The shares of the company saw a spurt in volume by more than 3 times on BSE. In the recent trading session, the stock has been hitting 10 consecutive upper circuits.
Sudarshan Pharma Industries Limited (SPIL), founded in 2008, is a Mumbai-based contract manufacturer of generic formulations. It operates in various segments, including specialty chemicals, intermediates, APIs, pharma and formulation generics, and bulk supply. SPIL sources and supplies pharmaceutical products to various institutions and healthcare organizations. Through its Vimac Healthcare division, it manufactures and sells its own branded products, with 56 out of 96 products registered under the "R" trademark. Additionally, SPIL provides contract manufacturing services for pharmaceutical formulations and medicines to well-known companies in India and institutional customers.
DSIJ’s ‘Micro Marvel' service recommends micro-cap stocks with the potential to grow multifold in long run. If this interests you, do download the service details here.
Sudarshan Pharma Industries Ltd has recently expanded its operations by incorporating a new subsidiary, Sudarshan Maven Pharma Private Limited. Sudarshan Pharma has taken a significant stake in Sudarshan Maven, subscribing to 70 per cent of its equity share capital. The newly formed subsidiary is primarily engaged in the manufacturing and development of various pharmaceutical products, including APIs, intermediates, and antibiotics. It also deals in healthcare products, Ayurvedic supplements, and medicinal preparations. Sudarshan Maven's acquisition aligns with Sudarshan Pharma's existing business and is expected to contribute to the growth and diversification of its operations in the chemical and pharmaceutical sectors.
The company has a market cap of Rs 660 crore and has delivered good profit growth of 37 per cent CAGR over the last 5 years. The stock gave multibagger returns of 371.65 per cent from its 52-week low of Rs 58.20 per share. Investors should keep an eye on this micro-cap stock.
Disclaimer: The article is for informational purposes only and not investment advice.
Also Read: 1,15,000 per cent returns & Rs 76,705 crore order book: Multibagger defence company bags new orders worth Rs 1,155 crore from Cochin Shipyard Ltd & others